What Did the FDA Approve for Thyroid Eye Disease in October 2026?
Enspryng (satralizumab-mwge) is an IL-6 receptor inhibitor from Genentech that the FDA approved on October 15, 2026, as the first at-home subcutaneous treatment for thyroid eye disease. As of October 2026, it joins two infused options, Tepezza and Lumvoa, which means TED treatment now runs through both the medical benefit and the pharmacy benefit, each with different coding, authorization, and revenue rules.
The billing shift: Self-injected Enspryng typically moves through the pharmacy benefit, while infused Tepezza and Lumvoa stay on the medical benefit.
The diagnosis code: The FY 2027 ICD-10-CM code set reports TED with H05.83-, plus a code-also note for the underlying thyroid condition.
The first step: Update prior authorization checklists now, because payer drug policies often lag a new approval.
What the FDA Approved on October 15, 2026
On October 15, 2026, the FDA approved Enspryng for thyroid eye disease, according to Genentech and parent company Roche. Enspryng is an interleukin-6 receptor inhibitor that patients or caregivers can inject under the skin at home after training from a healthcare provider. It is not a new molecule: the FDA first approved it in 2020 for neuromyelitis optica spectrum disorder, and the TED indication came through a priority review with an October 15 action date.
The approval rests on two phase 3 trials, SatraGO-1 and SatraGO-2, which together enrolled 258 patients and measured whether eye bulging improved by at least 2 mm at week 24. In SatraGO-2, 53% of Enspryng patients met that proptosis target versus 23% on placebo. SatraGO-1 showed a smaller gap, 49% versus 39%, and fell short of the SatraGO-2 result.
Enspryng is the third FDA-approved TED therapy. Here is how the three compare for billing purposes:
| Therapy | FDA approval for TED | How it is given | How it is usually billed |
|---|---|---|---|
| Tepezza (teprotumumab-trbw) | 2020 | IV infusion, 8 infusions every 3 weeks | Medical benefit, J3241 per 10 mg, plus infusion administration |
| Lumvoa (veligrotug-vvze) | June 26, 2026 | IV infusion, 5 infusions every 3 weeks | Medical benefit; no product-specific code in CMS’s October 2026 file |
| Enspryng (satralizumab-mwge) | October 15, 2026 | Subcutaneous injection at home after training | Typically pharmacy benefit, dispensed by a specialty pharmacy |
As of mid-October 2026, trade press reported that Genentech had not announced a specific date for TED availability, although Enspryng is already sold for its neurology indication.
Who Does the Enspryng Approval Affect?
The approval affects ophthalmology practices that diagnose or co-manage thyroid eye disease, especially oculoplastic, orbital, and neuro-ophthalmology specialists, plus the endocrinology offices that refer to them. It also affects billing teams, because TED treatment can now run through the pharmacy benefit as well as the medical benefit.
Genentech puts TED at roughly 155 people per 100,000, and most patients have Graves’ disease. Many of them already see an ophthalmologist for proptosis, double vision, or eyelid retraction, so even general ophthalmology practices will field questions about the new option.
The practical split looks like this. Practices that infuse Tepezza or Lumvoa in the office, or send patients to an infusion center, keep their current buy-and-bill workflow for those drugs. Practices without infusion capacity may now prescribe Enspryng and manage the case without a chair, but they inherit a different administrative job: benefits investigations, specialty pharmacy coordination, and documenting injection training.
One question we hear constantly from practice managers is whether a new drug really changes what their billing team must handle. With TED, it does, because the drug may never appear on the practice’s claim at all while the authorization work still lands on the front desk.
Patients feel the shift too. A Medicare patient on an infused TED drug faces Part B coinsurance, while a patient on a self-injected drug depends on Part D or commercial pharmacy coverage, so cost conversations move to a different benefit. Billing staff should expect more benefit verification calls for TED patients and confirm which benefit applies before the first treatment visit.
Why the Benefit Channel Changes Billing
Medicare Part B pays for drugs furnished incident to a physician’s service, such as an infusion given in the office, but it generally excludes drugs that patients usually administer themselves. That rule, described in Chapter 15, Section 50.2 of the Medicare Benefit Policy Manual, is why a self-injected biologic typically moves to Part D or to a commercial plan’s pharmacy benefit.
The two channels run on different machinery. Medical benefit drugs are billed with HCPCS codes, billing units, and NDCs, and they are priced in Medicare’s quarterly payment limit files. In CMS’s October 2026 Part B payment limit file, Tepezza’s code, J3241, pays up to $381.627 per 10 mg unit. Neither Lumvoa nor Enspryng appears in that file with its own code.
Payer policies are also catching up. A UnitedHealthcare Community Plan medical benefit drug policy effective October 1, 2026, covers Lumvoa and Tepezza together and adds a sequencing rule: Lumvoa is for patients who have not previously received Tepezza, and Tepezza is for patients who have not previously received Lumvoa. That policy does not address Enspryng, which would typically fall under pharmacy benefit rules instead.
The signal for practices is that TED has become a multi-channel condition. A single patient could start on one therapy, hit a coverage wall, and move to another channel entirely. Billing teams that only know buy-and-bill, or only know pharmacy authorizations, will struggle with the handoffs. Practices should expect a few months of mixed rules while payer policies, formularies, and coding catch up to three therapies instead of one.
How Does Enspryng Change TED Revenue for a Practice?
It means the practice may stop billing the drug itself for some TED patients. Infused TED drugs generate a drug line and an infusion administration line on the practice or facility claim, while a self-injected drug is dispensed by a specialty pharmacy, leaving the practice to bill visits, testing, and training instead.
Consider a 70 kg Medicare patient on a full Tepezza course. The labeled dosing is 10 mg/kg for the first infusion, then 20 mg/kg every 3 weeks for seven more infusions, which adds up to 1,050 billing units of J3241. At CMS’s October 2026 payment limit of $381.627 per unit, that course totals about $400,708 in allowed drug payment, and each maintenance infusion is about $53,428. Medicare pays 80% of the allowed amount after the deductible, and the patient or a supplemental plan owes the rest.
At those amounts, one denied infusion claim is a five-figure problem. Tepezza comes in 500 mg vials, so most weight-based doses leave discarded drug that must be reported with the JW modifier, or the JZ modifier when nothing is discarded. Buy-and-bill practices also carry inventory risk: CMS’s crosswalk treats each 500 mg vial as 50 billing units, about $19,081 at the October 2026 payment limit, so a cancelled infusion or an unpaid claim ties up real cash.
If that same patient were treated with Enspryng instead, none of the drug payment would run through the practice. The practice would still bill its evaluation and management or eye exam visits, monitoring tests such as visual fields, and any covered training visit, but its TED revenue forecast would look very different.
How to Prepare Your Billing Team for Three TED Therapies
Work through these seven steps before Enspryng prescriptions start:
- Code TED to H05.83- with laterality. Use H05.831, H05.832, H05.833, or H05.839, and code also the thyroid condition, such as E05.00 or E06.3, when it applies.
- Separate the authorization workflows. Run medical benefit requests for Tepezza and Lumvoa apart from pharmacy benefit requests for Enspryng.
- Document activity and severity at every visit. Payers commonly ask for a clinical activity score, proptosis measurements, diplopia status, and thyroid status.
- Bill infused drugs in correct units. Report J3241 per 10 mg and add JW or JZ for single-dose vials.
- Follow unclassified-drug rules for Lumvoa. Until a product-specific code appears in CMS’s quarterly files, payers generally expect an unclassified code with the NDC, dose, and invoice.
- Coordinate with the specialty pharmacy. Track benefits investigations, approvals, and training documentation for Enspryng patients.
- Review TED denials monthly by channel. Separate medical benefit denials from pharmacy benefit rejections to spot the real bottleneck.
Monitoring tests deserve the same attention. Visual fields and optic nerve imaging are central to watching for compressive optic neuropathy, and each test needs a diagnosis that supports medical necessity. Our 92083 CPT code guide covers visual field billing rules in detail. Optic nerve OCT, CPT 92133, often accompanies those fields when the physician is watching for optic nerve involvement, so record the reason for each test in the note, not just the order.
Across the billing companies we vet, the ones that handle specialty drugs well keep medical benefit and pharmacy benefit authorizations in separate queues with separate owners, so neither stalls the other.
Need a billing partner that handles both buy-and-bill infusions and pharmacy benefit authorizations? We’ll match your practice with a vetted ophthalmology billing company, typically in touch within 2 hours, with rates starting as low as 2.95%.
Common Mistakes With New TED Therapies
New drugs expose old habits. These are the mistakes most likely to cost TED practices money in the months after the approval.
Coding TED with generic codes. Exophthalmos codes in H05.24- or a thyroid code alone miss the specific H05.83- code the FY 2027 tabular provides for thyroid orbitopathy, including Graves’ ophthalmopathy and thyroid eye disease.
Billing Enspryng as a Part B drug. Self-administered drugs are generally excluded from Part B, so a Part B drug line for a self-injected product invites denial.
Assuming payer policies list Enspryng on day one. Coverage policies often update after an approval, so early requests may need a medical exception or extra documentation.
Switching between infused therapies without checking sequencing rules. Some payers, including the UnitedHealthcare Community Plan policy above, restrict moving from one IGF-1R therapy to the other.
Skipping wastage modifiers. A missing JW or JZ modifier on a single-dose vial claim is an avoidable denial on a very expensive line.
Under-documenting severity. Payers judge medical necessity from the chart. Notes that skip activity scores, measurements, or diplopia findings weaken every authorization request.
Treating monitoring tests as routine. Visual fields and imaging still need a supporting diagnosis and a documented reason each time.
Missing the code-also instruction. H05.83- carries a note to code also the associated thyroid condition, and leaving it off weakens the medical necessity picture for drug authorizations.
Each of these is preventable with a clear workflow, and fixing them early protects revenue for all three therapies while payer policies settle.
In-House Billing vs. a Specialty Billing Partner
In our experience matching ophthalmology practices with billing partners, specialty drugs are where in-house teams most often fall behind, because the work spans coding, payer policy, pharmacy coordination, and high-dollar claim follow-up at once.
Ophthalmology Bill Co has connected more than 200 ophthalmology practices with a network of over 30 billing companies, and we have facilitated more than 1,000 quotes and consultations. Partners in the network hold certifications from organizations including AAPC, AHIMA, and MGMA, maintain an average Google rating above 4.7, and serve every ophthalmology subspecialty in all 50 states. Many practices see denial rates fall 5 to 7% within 90 days of being matched, and many report reimbursement rate increases of upwards of 20% by the time they renegotiate contracts in year one.
Tim Daniels, Director of Strategic Accounts at Billing Service Quotes, works with specialty practices comparing billing partners, and benefit-channel experience is a fair question to ask any candidate. Ask how they handle J3241 units and wastage, unclassified drug claims, and pharmacy benefit appeals. Their denial rates on high-dollar drug claims and their turnaround time on prior authorizations will tell you more than a headline billing rate.
An in-house team can still work well for practices with steady TED volume and a dedicated authorization specialist. For practices without that depth, a specialty partner can absorb the new workload. Practices that already outsource can treat this approval as a checkpoint to confirm their partner is ready for TED volume across both benefit channels. Learn how matching works on our process page, or read more about Ophthalmology Bill Co.
Frequently Asked Questions
Enspryng (satralizumab-mwge) is FDA-approved for neuromyelitis optica spectrum disorder, approved in 2020, and for thyroid eye disease in adults, approved on October 15, 2026. It is a subcutaneous injection that patients or caregivers can give at home after training from a healthcare provider.
Generally no. Medicare Part B excludes drugs that patients usually self-administer, so a self-injected biologic such as Enspryng is typically covered, if at all, through Part D or a commercial pharmacy benefit. Confirm coverage with each patient’s plan before starting treatment.
The FY 2027 ICD-10-CM code set reports thyroid eye disease with H05.83-, Thyroid orbitopathy: H05.831 for the right orbit, H05.832 for the left, H05.833 for bilateral, and H05.839 for unspecified. Code also associated conditions such as autoimmune thyroiditis, E06.3, or thyrotoxicosis with diffuse goiter, E05.0-.
Tepezza (teprotumumab-trbw) is billed with HCPCS J3241, Injection, teprotumumab-trbw, 10 mg. Each billing unit is 10 mg. CMS’s October 2026 Part B payment limit file lists J3241 at $381.627 per unit for dates of service from October 1 through December 31, 2026.
As of the CMS October 2026 Part B payment limit file, Lumvoa (veligrotug-vvze) does not appear with a product-specific HCPCS code. Payers generally expect an unclassified drug code with the NDC, dose, and invoice until a dedicated code takes effect, so check each quarterly update.
The clinical decision belongs to the physician, but coverage may be restricted. A UnitedHealthcare Community Plan policy effective October 1, 2026, covers Lumvoa only for patients without prior Tepezza treatment, and Tepezza only for patients without prior Lumvoa. Check each payer’s policy before switching.
Next Steps
- Billing visual fields for TED monitoring? See our 92083 CPT code guide.
- Want to see how billing partner matching works? Read about our process.
- Ready to compare billing partners? Start at the Ophthalmology Bill Co homepage.
Get matched with a certified ophthalmology billing partner that handles specialty drugs, with rates starting as low as 2.95%.
